

**Notice Regarding Adjustment of 340B Prices for Select Products of Millennium Pharmaceuticals
(Takeda Oncology)**

Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ("Takeda Oncology") has recalculated its 340B ceiling prices for certain products for the period from Q2 2016 through Q3 2018 (the "Restatement Period").

As part of Takeda Oncology's effort to maintain compliance and accuracy with regard to its Government Pricing calculations, the company engaged in a voluntary self-evaluation and audit of its current processes and calculation methodologies. The recalculation of ceiling prices is due to revisions to the Medicaid pricing data for the product Velcade - NDC listed below:

<u>NDC</u>	<u>Product Description</u>
63020-0049-01	VELCADE 3.5MG F/INJ VIAL

Takeda Oncology, has determined the credit amount owed to each affected covered entity. Takeda Oncology, will be working with Apexus, LLC ("Apexus"), the 340B Prime Vendor, to validate wholesaler pharmacy account information for each covered entity. If a wholesaler account is identified, Takeda will issue a credit to the Covered Entity through the wholesaler, and a check will be issued to Covered Entities whose wholesaler account cannot be identified.

If any 340B Covered Entity that purchased VELCADE® during an impacted quarter, as identified above, has not received a notification from Apexus on behalf of Millennium Pharmaceuticals, and believes it may be eligible for a refund, or has questions regarding the refund process, please send an email to Apexus LLC, care of Millennium Pharmaceuticals, at refunds@apexus.com.